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Other names: CIS-2, Cytokine-inducible SH2 protein 
2; CIS2, STAT induced STAT inhibitor-2; Cish2, 
STAT-induced STAT inhibitor 2; SOCS-2, suppressor 
of cytokine signaling 2; SSI-2, suppressor of cytokine 
signaling-2; SSI2; STATI2 
Location: 12q21.33 
Local order:  By cytogenetic and radiation hybrid 
mapping, SOCS-2 has been mapped to chromosome 
12q21.3-q23 (Yandava et al., 1999). 
DNA/RNA 
Description 
6,38 kb; 3 exons. Mouse SOCS2 gene is composed of 3 
exons and 2 introns (Metcalf et al., 2000). Human 
SOCS-2 is a functioning gene that comprises 3 exons 
spanning roughly 6,38 kb of genomic DNA. 
Transcription 
2210 bp mRNA. 1 protein (22.2 kDa; 198 aa). 
Although constitutively expressed SOCS2 mRNA has 
been detected in several tissues and cell types, its 
expression is, in general, induced by stimulation with 
different cytokines and hormones (Rico-Bautista et al., 
2006). SOCS2 promoter analysis indicates the presence 
of AhR and STAT5 binding sites that confer 
responsiveness to dioxin (Boverhof et al., 2004) and 
GH (Vidal et al., 2006), respectively. 
Protein 
Description 
22.2 kDa; 198 aa. 
Expression 
SOCS mRNA and protein levels are constitutively low 
in unstimulated cells, but their expression is rapidly 
induced upon cytokine stimulation, thereby creating a 
negative feedback loop. Its expression is, in general, 
induced by stimulation with different cytokines and 




SOCS mechanisms of action rely on their ability to 
bind tyrosine phosphorylated proteins through their 
SH2 domains, but also to bind Elongin BC through 
their SOCS box domains. SOCS family proteins form 
part of a classical negative feedback system that 
regulates cytokine signal transduction (Rico-Bautista et 
al., 2006). SOCS2 appears to be a negative regulator in 
the growth hormone/IGF1 signaling pathway (Metcalf 
et al., 2000). SOCS2 appear to be involved in 
regulating protein turnover, targeting proteins for 
proteasome-mediated degradation (Rico-Bautista et al., 
2004). 
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Diagram representing the structure of SOCS proteins. At least eight proteins belonging to the SOCS family of proteins are shown (upper 
panel). They are characterized by the presence of an SH2 central domain and the SOCS box domain at the C-terminus. A small domain 
called kinase inhibitory region (KIR), only found in SOCS1 and SOCS3, is shown as a small box at the N-terminal region. SOCS proteins 
can interact with phosphotyrosine phosphorylated proteins through their SH2 domain and with Elongin BC through their SOCS box 
domain. Other proteins containing a SOCS box domain but lacking a SH2 domain are also shown (lower panel). Adapted from Elliot and 
Johnston (Elliott and Johnston, 2004) with modifications. 
Mutations 
Note: SNP: increasing the risk of type 2 diabetes. 
Implicated in 
Diabete 
Note: Susceptibility to type 2 diabetes (Kato et al., 
2006). 
Metabolism 
Note: SOCS2 null mice are giants but not obese 
(Metcalf et al., 2000). SOCS2 deficient mice have 
some metabolic characteristics that can be related to the 
enhanced GH actions (Rico-Bautista et al., 2005). 
Bone 
Note: Analysis of SOCS2 null mice have revealed that 
the absence of SOCS2 induces a reduction in the 
trabecular and cortical volumetric bone mineral density 
(Lorentzon et al., 2005). SOCS2 induces the  
 
 
differentiation of C2C12 mesenchymal cells into 
myoblasts or osteoblasts (Ouyang et al., 2006). 
Neural development 
Note: SOCS2 plays a critical role in neuronal 
development, growth, and stem cell differentiation 
(Turnley et al., 2002). 
Cancer 
Note: SOCS2 has been associated with cancer such as 
myeloid leukaemia, pulmonary adenocarcinoma, and 
ovarian cancer, breast cancer, and anal cancer. 
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